Maravai LifeSciences Holdings, Inc. (‘Maravai’), a life sciences company, provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics.
The company’s solutions empower research into human diseases and support the entire biopharmaceutical development process – from early discovery to commercialization. The company serves a diverse global customer base, including the world’s top biopharmaceutical companies ranked by res...
Maravai LifeSciences Holdings, Inc. (‘Maravai’), a life sciences company, provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics.
The company’s solutions empower research into human diseases and support the entire biopharmaceutical development process – from early discovery to commercialization. The company serves a diverse global customer base, including the world’s top biopharmaceutical companies ranked by research and development investment, emerging biotech firms, renowned academic research institutions, and leading in vitro diagnostics companies.
The company’s comprehensive product portfolio addresses the critical stages of biopharmaceutical development, offering complex nucleic acids for vaccine, therapeutic, and diagnostic applications; custom enzymes for research and diagnostic use; and antibody-based solutions to detect impurities during the production of biopharmaceutical products.
At Maravai, the company is committed to supporting its customers throughout their journey – from early discovery to commercialization – helping bring life-changing innovations to patients worldwide.
The company’s Strategic Priorities for Sustainable Growth are to deliver solutions from across its portfolio that help to accelerate discoveries and create exceptional customer experiences; take reflects its commitment to excellence, knowing that its products and services ultimately impact human lives; and harness the power of diverse perspectives and experiences to drive forward-thinking innovations together.
The company ships a significant portion of its products to its customers through independent package delivery companies, such as World Courier, FedEx, UPS, and DHL.
Business Segments and Products
The company reports its business in two reporting segments – Nucleic Acid Production and Biologics Safety Testing.
The company markets its Nucleic Acid Production business under the TriLink BioTechnologies, Glen Research, and Alphazyme brands. The company’s Biologics Safety Testing business consists of Cygnus Technologies.
Nucleic Acid Production
The company is a global provider of highly modified, complex nucleic acids and related products. It has recognized expertise in complex chemistries and products provided under exacting quality standards. The company’s core offerings include mRNA, long and short oligonucleotides, its proprietary CleanCap mRNA capping technology, mRNA building blocks, oligonucleotide building blocks, and specialty enzymes. The company’s offerings address key customer needs for critical components, from research to good manufacturing processes (‘GMP’) grade raw materials and active pharmaceutical ingredient (‘API’) manufacturing. The nucleic acid production market includes the production and synthesis of reagents for research and manufacturing of DNA and RNA-based biologics, including cell and gene therapies, mRNA therapeutics, and synthetic biology approaches.
mRNA lies at the core of the company’s capabilities and expertise. It has developed significant proficiency in mRNA technology, driven by its belief in its transformative potential as a therapeutic modality. Over 1,500 clinical trials are now in the pipeline, encompassing a wide range of medical applications.
These trials include vaccine development programs targeting infectious diseases, such as avian flu, Lyme disease, malaria, HIV, tuberculosis, shingles, rabies, yellow fever, respiratory syncytial virus (RSV), and Zika. Beyond infectious diseases, mRNA-based programs are addressing various medical conditions, including ornithine transcarbamylase deficiency, glycogen storage disorders, alpha-1 antitrypsin deficiency, acute lymphoblastic leukemia, Hurler syndrome, ovarian cancer, cardiovascular disease, and autoimmune disorders.
Cell and gene therapy programs also leverage mRNA across multiple therapeutic modalities, such as CRISPR/Cas9, transcription activator-like effector nucleases (TALENs), enzyme replacement therapies, allogeneic CAR-T cells, and base editing. These advancements underscore the broad and growing impact of mRNA technology in revolutionizing healthcare.
The company offers the following nucleic acid products: mRNA, RNA Capping (CleanCap), oligonucleotides, oligonucleotide synthesis inputs, nucleoside triphosphates, custom nucleic acid chemistry, and specialty enzymes. The company also offers Discovery/RUO and good manufacturing processes (‘GMP’) mRNA synthesis through its manufacturing services.
mRNA: The company develops and manufactures mRNA products to support vaccine and therapeutic programs from pre-clinical development through and including clinical phases, including scale-up and analytical development services. The company offers both research-grade material and material made under GMP conditions to support all phases of development.
RNA Capping: Within the mRNA category, the company also offers its patented CleanCap technology. CleanCap analogs principally serve the mRNA vaccine and therapeutics markets. The company offers a suite of CleanCap analogs that are specifically made for therapeutics and vaccines. The company’s cap analogs are a critical component of several mRNA vaccines and therapies in development.
The company offers several variations of the CleanCap molecule, serving the needs of mRNA and self-amplifying RNA developers. CleanCap is available in two quality grades, research use only for discovery and development activities, and a GMP-grade for clinical and commercial applications. The company’s newest CleanCap analog, CleanCap M6, was introduced in May 2023 and is its most robust cap analog to date, enabling mRNA that delivers higher levels of protein production.
Oligonucleotides: The oligonucleotide product category supports broad customer applications, including therapeutics, in vitro diagnostics, NGS, and CRISPR-based gene editing. Most of the company’s TriLink BioTechnologies oligonucleotide products are custom manufactured DNA or RNA sequences, often highly modified and produced as research use only (‘RUO’) or under GMP conditions for use in development, clinical, and commercial applications.
Oligonucleotide Synthesis Inputs: The company’s product offerings through Glen Research include reagents and support supplies for DNA and RNA oligonucleotide synthesis, labeling, modification, and purification. The company is a reputable and trusted vendor with a large portfolio, quality brand, knowledgeable technical support, and responsive customer service. In addition to oligonucleotide synthesis service providers, the company’s customer base includes life science, biopharma, and diagnostic companies, academic institutions, and government organizations, all of which internally manufacture their own oligonucleotide products.
Nucleoside Triphosphates: Nucleoside triphosphates (‘NTPs’) are the precursors to DNA and RNA. They are composed of a nitrogen base bound to either ribose or deoxyribose with three phosphate groups added to the sugar. The company manufactures NTPs that are used in polymerase chain reactions, in sequencing reactions, and in the manufacture of mRNA. The NTPs can be unmodified, composed of the four standard bases, or modified, with a base altered to enhance a particular biological property, such as the ability to evade the innate immune system in therapeutic applications. TriLink BioTechnologies NTPs are used by customers in both research and clinical trial applications. The company’s manufacturing capabilities for NTPs now include both RUO and GMP-grade.
Custom Nucleic Acid Chemistry: TriLink BioTechnologies has synthetic chemistry expertise and proprietary manufacturing processes allowing for the highest purity NTP, amidite, and custom nucleotide services. The company serves a diverse market of diagnostics and therapeutic developers that require novel molecules that are otherwise unavailable on the market. Typically, these molecules are initially manufactured in small quantities, and then scaled to meet the need of larger diagnostic platforms or therapeutic applications once positive candidates have been identified by the customer.
Specialty Enzymes: Enzymes are critical to almost every phase of nucleic acid production and provide the key starting materials for the IVT process to make mRNA. Alphazyme provides custom, scalable molecular biology enzymes with a full product line of in vitro transcription (‘IVT’), NGS, life science, and diagnostic enzyme solutions. Alphazyme enzymes are also incorporated into the TriLink Biotechnologies CleanScript mRNA production workflow.
Discovery mRNA synthesis: Through TriLink BioTechnologies, the company offers a core set of products and services geared toward customers doing early-stage development work. The company produces mRNA utilizing standard sequences for generalized research or using customer supplied sequences for custom built constructs. The company also provides process development services to optimize customers’ transcription and purification processes. These services can integrate with the company’s cap analogs, NTP products, and IVT enzymes and have access to its analytical and QC method development.
GMP mRNA synthesis: The company’s TriLink BioTechnologies GMP mRNA manufacturing services offer a clear pathway for customers running clinical trials. The company focuses on building partnerships with its customers in the emerging market of cell and gene therapy to ensure it is well-positioned to be an extension of their development teams. The company’s services feature robust quality management systems and include process development and scale-up, phase-appropriate regulatory submission support, and in-house analytical services for mRNA analysis and characterization.
Biologics Safety Testing
The company’s biologics safety testing products are used during development and scale-up, during the regulatory approval process, and throughout commercialization. The company is recognized globally for the detection of host cell proteins (‘HCPs’) and process-related impurities during bioproduction.
The company’s customers in this segment manufacture a broad range of biopharmaceutical products. These include monoclonal antibodies and recombinant proteins, both as novel biologics and biosimilars, and recombinant vaccines, including oncolytic vaccines to treat cancer. The company also provides products that support the development and commercialization of cell and gene therapies. Recombinant vaccines and cell and gene therapies rely on the manufacturing of various viral vectors produced using recombinant nucleic acid and cell culture technologies. Viral vector manufacturing processes require rigorous analytics, including testing for process-related impurities, such as HCPs, host cell DNA, purification leachates, growth media additives, and enzymes used in viral vector purification processes. All of the 24 existing FDA-and EMA-approved CAR-T Cell and Gene Therapies use Cygnus Host Cell Protein enzyme-linked immunosorbent assay (‘ELISA’) kits for HCP testing for commercial product lot release. Five of these 24 therapies were approved in 2024.
The trend in recent years has been for customers to increasingly use generic assays throughout their development and commercialization pathway, relying on the company’s expertise and the established performance of its assays supported by its comprehensive state-of-the-art assay qualification services. If customers choose to develop process-specific assays, the company offers custom antibody production and assay development, as well as characterization services to meet their needs.
The company’s comprehensive catalog of Cygnus Technologies HCP enzyme-linked immunosorbent assay (‘ELISA’) kits covers 25 expression platforms and provides the specificity and sensitivity to detect impurities with reproducibility, which supports regulatory compliance. The company’s reputation for quality is recognized by the industry and global regulatory agencies, with Cygnus Technologies assays used as reference methods throughout the industry and to support manufacturing and quality control of commercialized biologics and gene therapy products.
The company’s customers in this segment are biopharmaceutical companies, contract research organizations (‘CROs’), contract development and manufacturing organizations (‘CDMOs’), and life science companies.
Cygnus Technologies product categories include HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, viral clearance prediction kits, ancillary reagents, and custom services.
HCP ELISA Kits: HCP ELISA kits are bioassays used to detect residual proteins from the expression system used in bioproduction. HCPs constitute a major group of process-related impurities produced using cell culture technology, no matter what cell expression platform is used. HCPs pose potential health risks for patients and the risk of failure of safety endpoints for drug manufacturers. When present in the administered product, even at low levels, HCPs can induce an undesired immune response, interfere with drug efficacy, and impact drug stability. HCPs are a critical quality attribute for biologics safety testing development and must be adequately removed during the downstream purification process.
Other Impurity and Contaminant Kits: The company’s products in this category include kits for measuring Protein A leachate, which results from the affinity purification method used for monoclonal antibody therapeutic agents; ELISA kits for measuring additives in growth media, such as bovine serum albumin; kits for measuring host cell DNA; ELISA kits to detect and quantify residual endonuclease impurities in recombinant viral vector and vaccine preparations; and ELISA kits to quantify residual AAV2, AAV8, and AAV9 ligands resulting from the affinity purification method used for adeno-associated virus (AAV)-based gene therapies.
Viral Clearance Prediction kits: Following the company’s 2020 acquisition of the MockV technology, Cygnus Technologies has introduced the Minute Virus of Mice kit and the MockV RVLP Kit, which are novel, proprietary viral clearance prediction tools that include a non-infectious ‘mock virus particle’ mimicking the physicochemical properties of live virus that may be present endogenously in the drug substance or introduced during bioproduction. These kits enable manufacturers to conduct viral clearance assessments easily and economically and to predict outcomes in-house ahead of costly and logistically challenging live viral clearance studies.
Ancillary Reagents: The company’s ancillary reagent products include antibodies, antigens, sample diluents, and other auxiliary products necessary to optimize applications for customer processes.
Custom Services: The company provides process-specific antibody and ELISA development, qualification, and maintenance services. In addition, the company has pioneered advanced orthogonal methods, including antibody affinity extraction (AAE), mass spectrometry for HCP antibodies coverage analysis, and HCP identification, which it provides as custom services.
Commercial
The company has relationships with the following categories of customers: developers of therapeutics, cell and gene therapies, and vaccines; other biopharmaceutical and life science research companies; academic institutions; and molecular diagnostic companies. The company’s biopharmaceutical customers include startups, established biotechnology companies, and large pharmaceutical companies developing enzyme replacement therapies, gene editing therapies, ex vivo therapies, and vaccines.
The company’s commercial function includes direct sales, marketing, customer service, technical support, quoting and proposals, client program management, and channel management. The company serves customers through direct and indirect sales in each business segment, with a primary focus on its biopharmaceutical and large diagnostics and commercial customers. The company serves its academic customers via web, email, and phone ordering, as well as through key partnerships where its reagent products and services can be accessed through partnerships. The company supports all customers in-field and in-house technical support, alliance and program management, and customer service.
The company addresses customers outside the United States with a combination of direct sales and distributors. The company serves many of its biopharmaceutical customers, especially in its nucleic acid production segment, via direct sales worldwide. The company’s distributors also serve its customers in over 40 countries and provide customer service and local sales and marketing.
Competition
Nucleic Acid Production
For mRNA capping analogs, the company competes principally with Thermo Fisher Scientific, Aldevron (a subsidiary of Danaher), and New England Biolabs, who offer alternatives to CleanCap with enzymatic capping solutions.
For the company’s mRNA offerings, it competes with Aldevron, Patheon, eTheRNA, Lonza, Catalent, and Samsung Biologics, among others.
In the oligonucleotide synthesis inputs market, the company competes against large distributor-manufacturers like Thermo Fisher and Millipore Sigma while also serving them as customers.
For the company’s specialty enzymes offering, it competes with New England Biolabs, Thermo Fisher, QIAGEN, and Roche, among others.
Biologics Safety Testing
For drugs in early development, the company competes against other bioprocess impurity kit providers, such as BioGenes (‘BioGenes’) or Enzo Life Sciences (‘Enzo’).
For custom assay development, the company’s main competitors are BioGenes, Rockland Immunochemicals, and some contract development and manufacturing organizations (‘CDMOs’) and contract research organizations (‘CROs’) with custom assay development capabilities.
Licenses and Collaborations
Broad Patent License Agreement
The company (through TriLink BioTechnologies) entered into a Nonexclusive Patent License and Material Transfer Agreement with The Broad Institute, Inc. (‘Broad’) effective as of July 5, 2017, and amended on September 29, 2017 (the ‘Broad Patent License Agreement’). Broad, together with a consortium of educational institutions (including Harvard University and the Massachusetts Institute of Technology), owns and controls certain patent rights relating to genome editing technology, including the CRISPR-Cas9 gene editing processes and has a licensing program for use and commercialization of technologies and products covered by the underlying patent rights. Under the Broad Patent License Agreement, Broad grants to the company a non-exclusive, royalty-bearing, non-transferable, and non-sublicensable, worldwide license under the licensed patent rights to manufacture and sell products and to perform certain in vitro processes or services on a fee-for-service basis, in each case, solely as research tools for research purposes (excluding human, clinical, or diagnostic uses).
Research Products
The company’s products and operations may be subject to extensive and rigorous regulation by the Food and Drug Administration (‘FDA’) and other federal, state, or local authorities, as well as foreign regulatory authorities. Certain of the company’s products are currently marketed as research use only (‘RUO’). The company’s products that are marketed as RUO products are exempt from compliance with GMP regulations under the Food, Drug, and Cosmetic Act (‘FDCA’).
Active Pharmaceutical Ingredients (‘APIs’) for Clinical Trials
The company provides APIs to customers for use in preclinical studies through and including clinical trials. The company holds a drug manufacturing license with the California Food and Drug Branch of the California Department of Public Health for the manufacture of APIs for clinical use and is subject to inspection to maintain licensure. Manufacture of APIs for use in clinical trials is regulated under § 501(a)(2)(B) of the FDCA, but is not subject to the current GMP regulations in 21 CFR § 211 by operation of 21 CFR § 210. The company follows the principles detailed in the International Council for Harmonisation (‘ICH’) Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Section 19, APIs For Use in Clinical Trials) in order to comply with the applicable requirements of the FDCA, and the comparable GMP principles for Europe; European Community, Part II, Basic Requirements for Active Substances Used as Starting Materials (Section 19, APIs For Use in Clinical Trials).
Intellectual Property
Patents
The company’s intellectual property strategy is focused on protecting, through patents and other intellectual property rights, its core products and services, including CleanCap, and related instrumentation and applications. In addition, the company protects its ongoing research and development into critical reagents for cell and gene therapy through patents and other intellectual property rights. The company’s patent portfolio generally includes patents and patent applications relating to compositions and methods for the production of CleanCap, oligonucleotides, nucleic acids, immunofluorescence assays, and mock viral particles.
Trademarks
The company’s trademark portfolio is designed to protect the brands of its current and future products and includes the U.S. trademark registrations for its company name, Maravai LifeSciences, subsidiary names Cygnus Technologies and TriLink BioTechnologies, and various product names, such as CleanCap and MockV.
Research and Development
The company incurred research and development expenses of $19.2 million for the year ended December 31, 2024.
History
Maravai LifeSciences Holdings, Inc. was founded in 2014. The company was incorporated as a Delaware corporation in 2020.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
